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Abstract
The prevalence of type 2 diabetes (T2D) has increased worldwide and doubled
over the last two decades. It features among the top 10 causes of mortality and
morbidity in the world. Cardiovascular disease is the leading cause of
complications in diabetes and within this, heart failure has been shown to be the
leading cause of emergency admissions in the United Kingdom. There are many
hypotheses and well-evidenced mechanisms by which diabetic cardiomyopathy
as an entity develops. This review aims to give an overview of these mechanisms,
with particular emphasis on metabolic inflexibility. T2D is associated with
inefficient substrate utilisation, an inability to increase glucose metabolism and
dependence on fatty acid oxidation within the diabetic heart resulting in
mitochondrial uncoupling, glucotoxicity, lipotoxicity and initially subclinical
cardiac dysfunction and finally in overt heart failure. The review also gives a
concise update on developments within clinical imaging, specifically cardiac
magnetic resonance studies to characterise and phenotype early cardiac
dysfunction in T2D. A better understanding of the pathophysiology involved
provides a platform for targeted therapy in diabetes to prevent the development
of early heart failure with preserved ejection fraction.
Key words: Diabetic cardiomyopathy; Cardiac metabolism; Myocardial steatosis;
Myocardial strain
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Core tip: Altered myocardial metabolism and impaired metabolic flexibility are key
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mechanisms implicated in diabetic cardiomyopathy. Glucotoxicity, lipotoxicity, coronary
microvascular dysfunction and suboptimal substrate utilisation are examined in detail.
The mechanisms implicated and the impact on myocardial structure and function have
been scrutinised within this review.
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INTRODUCTION
Type 2 diabetes (T2D) is now a global pandemic. The disease is characterised by
insulin resistance, relative impairment of insulin secretion and increased hepatic
glucose output resulting in high blood glucose levels. It is now among the top 10
causes  of  death  and represents  a  major  cause  of  mortality  and morbidity  in  the
world[1]. Globally there were 422 million patients with diabetes in 2014, with growing
prevalence from 4.7% in 1980 to 8.5% in 2014[2]. Heart failure (HF) has emerged as the
most common initial  cardiovascular complication of  diabetes[2,3].  T2D is  likely to
contribute to the development of HF through a variety of mechanisms, including
disease specific myocardial structural, functional and metabolic changes. In the 2015-
16  England  and  Wales  National  Diabetes  Audit,  there  were  115695  emergency
admissions for patients with diabetes and HF compared to 21399 with myocardial
infarction and 29392 with stroke[4]. Once HF diagnosis is established in T2D patients
over the age of 65, mortality risk increases tenfold, and five-year survival reduces to
12.5%[5].
The  diabetic  population  has  been  shown to  pose  a  marked preponderance  to
developing HF following a myocardial infarction[6-8]. In addition to this, systolic and
diastolic left ventricular dysfunction has also been described unrelated to the presence
of macrovascular coronary disease[9-11]. The prevalence of HF in the general population
has been estimated to be 11.8%[12], whereas in clinical trials of cardiovascular outcomes
in T2D patients, the prevalence of HF at baseline has varied between approximately
10% and 30% encompassing both HF with reduced ejection fraction (HFrEF) and HF
with preserved ejection fraction (HFpEF) with a doubling of the risk of developing HF
in those aged 75-84[13-23].
Diabetic  cardiomyopathy  is  defined  as  cardiac  dysfunction  encompassing
structural, functional and metabolic changes in the absence of coronary artery disease
(CAD)[24-26]. This distinct clinical entity was first proposed by Lundbaek[27] in 1954 as
diabetic heart disease independent of hypertension and CAD that commonly co-exist
with T2D. Rubler et al[9] in 1972 went on to confirm these observations, describing
diabetic-related post-mortem findings in four patients with T2D, glomerulosclerosis
and HFrEF with normal epicardial coronary arteries the absence of hypertension,
CAD, valvular or congenital heart disease. A large United States nationwide case-
control study by Bertoni et al[28] in 1995 further confirmed an association between non-
ischaemic idiopathic cardiomyopathy and diabetes. Another recent large population
study showed that despite good control of all cardiovascular risk factors, the risk of
HF hospitalisation in T2D was still consistently higher although there was little or no
increase in risk of mortality, myocardial infarction, or stroke in comparison to the
general population[29].
Experimental studies have shown that functional and structural alterations within
the diabetic heart may be caused by a significant difference in underlying metabolic
mechanisms  and  substrate  utilisation.  These  have  been  supported  by  multiple
hypotheses on how T2D disease processes affect the structure and function of the
myocardium  resulting  in  a  HF-like  phenotype [30].  The  aetiology  of  diabetic
cardiomyopathy is multifactorial. Despite decades of research aiming to determine
the causes of this distinct pathology, more research is needed. Current hypotheses
include insulin resistance, endothelial dysfunction, fibrosis, cardiac lipotoxicity and
energetic impairment. In particular, cardiac metabolism may play a central role in
diabetic cardiomyopathy.
Type  1  diabetes  (T1D)  is  a  condition  of  absolute  insulin  deficiency  due  to  T-
cell–mediated autoimmune destruction of pancreatic β-cells. Cardiovascular disease is
again  a  major  long-term  sequelae  of  the  disease  with  an  impact  on  healthcare
WJD https://www.wjgnet.com October 15, 2019 Volume 10 Issue 10
Athithan L et al. Diabetic cardiomyopathy
491
resources.  This  encompasses  coronary  artery  disease,  cerebrovascular  disease,
peripheral artery disease, heart failure and cardiomyopathy. The pathophysiology of
these  processes  vary  and  most  of  the  data  from  population  studies  and  large
databases  are  focused  on  T2D.  Studies  looking  at  atherectomy  samples  have
previously  shown  that  the  pathology  of  atherosclerosis  did  not  differ  between
diabetes type[31]. Angiographic evidence showed that T1D caused more multivessel,
distal and severe stenosis[32]. T1D appear to be affected more by hypoglycaemia and
inflammation. Inflammatory markers such as C reactive protein, interleukin receptors
and CD4 ligands are higher in T1D[33,34]. Excess adiposity and altered fat distribution
have been shown to contribute to diabetic cardiomyopathy in T1D similar to T2D. For
the purposes of this review, we will be focusing on the evidence base behind diabetic
cardiomyopathy in T2D.
MYOCARDIAL ENERGY METABOLISM
Normal vs the diabetic heart
The heart converts chemical energy present in the form of substrates and oxygen to
mechanical energy and heat[35,36].  Maintenance of adequate levels of cardiac high-
energy phosphate metabolites, adenosine triphosphate (ATP), the energy source for
contraction, and phosphocreatine (PCr), the major energy storage compound, are of
vital  importance  for  normal  heart  function[37].  A  healthy  heart  is  capable  of
metabolising a range of substrates, including fatty acid (FA), glucose, amino acids,
ketones and lactate, to produce ATP[38,39]. In the normal heart, the main substrates for
acetyl-CoA and therefore ATP formation are long chain FAs (60%-90%) and glucose
and pyruvate  oxidation (10%-40%,  formed from glycolysis).  The normal  cardiac
metabolic process involves energy transfer initially from substrate to the high energy
phosphate metabolite ATP. This occurs through the generation of acetyl-CoA, that
then enters the tricarboxylic acid cycle (TCA), also known as Krebs or citric acid cycle,
followed by oxidative phosphorylation[40] resulting in the production of ATP (Figure
1). This is then transferred through facilitated diffusion to the areas requiring the high
energy  released  through  ATP  hydrolysis,  i.e . ,  myosin  and  sarcoplasmic
reticulum[37,41-43]. Figure 2 shows the role of carnitine in the mitochondrial oxidation of
fatty acids contained within Figure 1. Figure 3 details the Randle cycle, also referred
to as  the glucose-fatty  acid cycle  which helps  regulate  uptake and utilisation of
glucose within the muscle dependent on the rate of fatty acid oxidation.
Altered  myocardial  substrate  metabolism  may  play  a  central  role  in  cardiac
dysfunction in T2D patients[40,44,45], by affecting myocardial oxygen demand which in
turn results in reduced metabolic flexibility[39,46,47]. Metabolic flexibility describes the
ability of an organism to respond to changes in metabolic or energy demand as well
as  the  prevailing  conditions  or  activity [38 ,39].  There  are  no  myocardial  ATP
reserves[35,48,49]. Energy in the heart is stored in three forms. The first form of stored
energy is phosphocreatine, which can rapidly donate its high energy phosphates to
produce ATP from ADP. The second endogenous form of energy is glycogen. The
third form of stored energy is represented by triglycerides.
Stress metabolism studies and metabolic flexibility
Myocardial substrate metabolism can be measured directly by cardiac catheterization
and transmyocardial blood sampling. Cardiac metabolic flexibility can be evaluated
by coronary sinus (CS) studies invasively and positron emission tomography (PET)
studies. Substrate concentrations in arterial and CS blood, in combination with the
measured CS flow, yield information about the myocardial use of substrates and
oxygen[50].  Simultaneous  CS and coronary  artery  blood sampling allow detailed
analyses  of  myocardial  substrate  metabolism  obtained  by  measuring  the
arteriovenous extraction of carbohydrates, fat, ketones, and amino acids. The flow in
the CS correlates with cardiac output, mean arterial pressure, and the flow through
the coronary arteries and varies with myocardial oxygen demand[51]. The technique
has been used in healthy individuals[52], in patients with dilated cardiomyopathy[53],
and syndrome X[54] during incremental pacing. These studies looked into FA, glucose
and lactate metabolism in the heart as key sources of energy production as well as
myocardial  oxygen consumption at  rest  and during periods of  increased cardiac
work.  They  confirmed  that  in  healthy  individuals,  cardiac  metabolism  relies
predominantly on oxidation of FAs, but during increased cardiac workload with
maximal  pacing  stress,  glucose  uptake  increases  by  a  factor  of  two,  while  FA
metabolism does not change. In summary these studies confirmed that, although FAs
are the predominant fuel for energy provision in the human heart in the resting state,
carbohydrates  are  the  fuel  for  the  heart  in  a  state  of  exercise  or  stress.  In  T2D,
WJD https://www.wjgnet.com October 15, 2019 Volume 10 Issue 10
Athithan L et al. Diabetic cardiomyopathy
492
Figure 1
Figure 1  An overview of myocardial energy substrate utilization. Fatty acids and glucose are the major substrates used for ATP generation. The pyruvate
generated from glycolysis is metabolised within the mitochondria to produce the majority of carbohydrate-derived ATP while fatty acids undergo β-oxidation. The
majority of myocardial ATP originates from the mitochondria via the Krebs Cycle. A preferential increase of activity in one pathway over the other can result in
imbalances in substrate uptake and utilization by the mitochondria[151]. GLUT 1: Glucose Transporter 1; GLUT 4: Glucose Transporter 4; FATP: Fatty Acid Transport
Protein; CAC: Citric Acid Cycle; ATP: Adenosine Triphosphate; CPT-1: Carnitine palmitoyltransferase-1; CPT-2: Carnitine palmitoyltransferase-2.
cardiomyocytes have been shown to exhibit insulin resistance, decreased glucose
utilisation  and  increased  fatty  acid  oxidation  in  response  to  stress,  insulin  or
variability in FA availability confirming that cardiac metabolic reserve is impaired in
diabetes[55].
Stress metabolism can also be assessed non-invasively by PET. There have been
only a few studies to date using PET to assess cardiac metabolism in patients with
T2D. However, there has been conflicting outcomes from these studies[56] regarding
the changes in myocardial glucose uptake and insulin resistance in T2D patients.
While one study showed reduced myocardial glucose uptake and myocardial insulin
resistance, another study showed preserved myocardial insulin responsiveness in
patients with T2D[46,57]. One small study using PET imaging to characterize myocardial
glucose  metabolism  in  patients  with  T2D  evaluated  the  influence  of  chronic
hypertriglyceridemia  on  myocardial  glucose  uptake.  They  compared  five  T2D
patients  with  high  triglyceride  (TG)  levels  to  11  T2D  patients  with  normal  TG.
Patients were matched by age, gender, blood pressure and glycaemic control. They
showed 40 and 65% lower myocardial glucose uptake in the high TG group compared
normal TG group, respectively, and evidence of myocardial insulin resistance in T2D.
Another small PET study assessing skeletal muscle and myocardial glucose uptake in
10  patients  with  T2D  compared  to  nine  age  and  weight-matched  healthy  male
controls under normoglycaemic hyperinsulinaemic conditions, showed preserved
myocardial glucose uptake[57].  A third PET study compared glucose utilization in
diabetic (n = 19) and nondiabetic CAD patients (n = 35) undergoing coronary artery
bypass graft surgery grafting surgery (CABG) also showed lower myocardial glucose
uptake  in  diabetic  cohort,  but  this  study  did  not  assess  myocardial  insulin
resistance[56].
Myocardial energetics
The phosphocreatine to ATP (PCr/ATP) ratio is a sensitive measure of myocardial
energetic status. 31-Phosphorus magnetic resonance spectroscopy (31P-MRS) provides
a non-invasive quantification of myocardial PCr/ATP. Normally, the body is able to
increase phosphotransferase reactions,  glycolysis  and glycogenolysis  to function
under higher energy demands[43,58,59]. Scheuermann-Freestone et al[60] pioneered the
study of  myocardial  energetics  in  2003 by studying cardiac  and skeletal  muscle
energetics in T2D. Twenty one diabetics and 15 controls were studied to determine
normal energy metabolism and the effect of T2D on circulating glucose and free fatty
acid concentrations. They showed that, in the presence of normal cardiac structure,
function and morphology, patients with T2D had 35% lower PCr/ATP ratios. There
was a significant negative correlation with fasting plasma FA concentration as well as
a significant  positive correlation with plasma glucose concentration in diabetics
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Figure 2
Figure 2  Carnitine shuttle system. This summarises the role of carnitine in the mitochondrial oxidation of fatty
acids; contained within Figure 1[152]. CPT-1: Carnitine palmitoyltransferase-1; CPT-2: Carnitine palmitoyltransferase-
2; OM: Outer mitochondrial membrane; IM: Inner mitochondrial membrane.
compared to  controls.  In  skeletal  muscle,  energetics  was  normal  at  rest,  but  the
decrease in PCr was faster during exercise in those with diabetes and the recovery
was  slower  after  exercise.  This  lends  credibility  to  the  theory  that  changes  in
myocardial and skeletal muscle energetics is part of the initial disease process in T2D
and this results in changes in substrate use and availability. Cardiac muscle is more
affected by the energetic alterations and substrate availability[60].
Shivu et al[61] the looked at 25 asymptomatic type 1 diabetics vs 26 healthy controls
who underwent 31P-MRS and adenosine stress cardiovascular magnetic resonance
(CMR) and again this showed significantly reduced PCr/ATP ratio in diabetics, both
long-term and newly-diagnosed, compared to healthy volunteers (2.23 ± 0.56 vs 1.49 ±
0.44,  respectively,  P  <  0.001).  Mean myocardial  perfusion reserve  index  (MPRI)
correlated negatively with duration of diabetes, with a significant reduction in long-
term diabetes (1.7 ± 0.6) compared to newly diagnosed subjects (2.1 ± 0.2, P < 0.05)
and controls  (2.3  ±  0.3,  P  =  0.05).  However,  there  was no significant  correlation
between PCr/ATP and MPRI  implying  the  myocardial  energetic  alteration  was
independent  of  any  coronary  microvascular  dysfunction  primarily  results  from
metabolic dysfunction[61].
Most recently, Levelt et al[62] have shown significant correlation between myocardial
systolic  strain  and  rest  and  stress  PCr/ATP  in  31  T2D  compared  to  16  healthy
controls.  Subjects  underwent  31P-MRS  performed  both  at  rest  and  exercise  and
adenosine stress CMR for assessment of perfusion by MPRI and oxygenation. The
PCr/ATP was 17% lower in T2D compared to controls (1.74 ± 0.26 vs  2.07 ± 0.35,
respectively, P  = 0.001) at rest,  with a further 12% reduction in PCr/ATP during
exercise in T2Ds. However, there was no change in PCr/ATP in the control group
during exercise. Similarly, MPRI was lower in diabetes (1.61 ± 0.43 vs 2.11 ± 0.68 in
controls,  P  = 0.002).  At rest,  no correlation was observed between PCr/ATP and
MPRI, but a significant correlation was noted during exercise. These findings support
the notion that under stress microvascular dysfunction may exacerbate energetic
derangement[62].
Cardiac metabolic reserve is impaired in diabetes. Lower metabolic reserve is likely
to be the consequence of impaired metabolic flexibility and may be associated with
increased mortality,  as has been shown in a small  study of patients with dilated
cardiomyopathy[63].
DIABETIC CARDIOMYOPATHY AND POTENTIAL
MOLECULAR MECHANISMS
Glucotoxicity
Activity of pyruvate dehydrogenase (PDH), which is a key enzyme that regulates the
balance  between  carbohydrate  and  fat  metabolism in  the  heart,  is  decreased  in
diabetes and pyruvate oxidation impaired[64,65].  Inhibition of PDH limits pyruvate
oxidation[66].  The dissociation of glycolysis and pyruvate oxidation in the diabetic
heart results in the accumulation of glycolytic intermediates[67]. Failure to adequately
control intracellular glucose levels has also been implicated in the development of
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Figure 3
Figure 3  Randle cycle. The glucose-fatty acid (Randle) cycle in muscle. Oxidation of fatty acids inhibits pyruvate dehydrogenase. Citrate inhibits
phosphofructokinase. The rise in glucose-6-phosphate inhibits hexokinase[153]. FFA: Fatty acids; HK: Hexokinase; PDH: Pyruvate dehydrogenase; PFK:
Phosphofructokinase; UDP: Uridine diphosphate; GLUT 4: Glucose transporter 4; OOA: Oxaloacetic acid.
insulin resistance and in the generation of  reactive oxygen species  (ROS).  These
glycolytic intermediates activate glucose sensing transcription factors[68,69]. It has been
previously postulated that accumulation of glycolytic intermediates decreases the
sarcoplasmic reticulum calcium ATPase 2a (SERCA2a) expression[70],  an essential
enzyme in calcium homeostasis, which results in diastolic dysfunction[71]. Confirming
this,  SERCA2a expression in the heart was shown to be decreased in response to
diabetes[71,72].
Lipotoxicity and myocardial steatosis
In diabetes, a decrease in insulin sensitivity leads to an inability to suppress lipase
within adipose tissue and very low-density lipoprotein within the liver. This results in
high levels of circulating FAs and as a consequence peroxisome proliferator activated
receptor-α (PPARα) activation, while decreasing glucose-transporter-4 activity[47,73].
PPARα is an essential component in cardiac substrate switching. Decreased PPARα
expression (due to pressure overload and/or prolonged exposure to hyperglycemia
and/or hyperlipidemia)  will  limit  the  FA oxidative  capacity  of  the  heart[74].  The
discordance between the rates  of  FA availability  and/or uptake with that  of  FA
oxidation results in increased intracellular long chain fatty acyl-CoA concentrations[46]
Since  cardiomyocytes  are  not  specialised  to  store  lipid,  this  finding  suggests  a
deleterious  effect,  and  cellular  lipid  overloading  underlies  the  concept  of
“lipotoxicity” as a potential mechanism for impaired cardiac function[75-78]. The excess
long chain fatty acyl-CoA is then diverted towards non oxidative processes with the
production of lipotoxic intermediates such as ceramide and diacyl-glycerol[47]. This is
postulated  to  be  a  potential  mechanism  for  impaired  cardiac  structure  and
function[76-79]. The molecular mechanisms described above that have been implicated
in the pathophysiology of diabetic cardiomyopathy are detailed in Figure 4.
Imaging myocardial triglyceride
Proton (1H)-MRS offers a non-invasive method to measure cardiac triglyceride (TG)
content. Using this methodology, studies have shown myocardial TG content to be
significantly raised in T2D (Table 1). The studies are all consistent in reporting an
increased hepatic triglyceride content in the diabetic population. Levelt et al[62] has also
recently shown that myocardial lipid level is a predictor of concentric LV remodelling
independent of BMI, systolic and diastolic blood pressure, and circulating FA, and is
associated with subclinical contractile dysfunction in T2D. The study recruited 46
non-hypertensive T2D patients and 20 matched controls. Seventy four percent of the
diabetic patients were on statin therapy resulting in lower total cholesterol and low-
density lipoprotein cholesterol levels in patients compared to controls. This provides
another avenue for potential therapy in T2D as myocardial steatosis has been found to
be  reversible  with  cholesterol  and  triglyceride  control  in  addition  to  glucose
control[80,81].
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Figure 4
Figure 4  Pathways of cardiac dysfunction leading to diabetic cardiomyopathy. Pathways leading to the development of diabetic cardiomyopathy[154]. AGE:
Advanced glycation end products; FA: Fatty acids; FFA: Free fatty acids; GLUT: Glucose transporters; PKC: Protein kinase C; PPARα: Peroxisome proliferator-
activated receptor alpha; ROS: Reactive oxygen species.
Increased myocardial TG content has been shown in T2D. Compared with lean
subjects, myocardial TG content was elevated 2.3-fold in impaired glucose tolerance
and 2.1-fold in T2D. This was evidenced in a cross sectional study looking at both lean
and increased BMI participants with and without T2D[82]. Myocardial TG has also been
shown  to  be  an  independent  predictor  of  left  ventricular  diastolic  function  in
multivariable analysis accounting for BMI, heart rate, visceral fat and diastolic blood
pressure. In a study of 38 T2D and 28 matched controls, myocardial TG measured by
(1H)-MRS  was  significantly  higher  in  T2D.  Although  there  was  no  significant
difference in systolic function,  all  indices of diastolic function were significantly
impaired in T2D[83]. Interestingly, calorific restriction in obese T2D patients on a very
low calorie diet of 450 kcal/d was been shown to decrease myocardial TG content
from 0.88 +/- 0.12% to 0.64 +/- 0.14%, respectively (P = 0.019) over a 16 wk period,
and this was associated with better diastolic function (E/A ratio from 1.02 +/- 0.08 to
1.18 +/- 0.06)[84].  Myocardial TG level is a predictor of concentric LV remodelling
independent of BMI, systolic and diastolic BP, circulating FA and is associated with
subclinical contractile dysfunction in T2D[62].
MYOCARDIAL STRUCTURAL AND FUNCTIONAL CHANGES
IN DIABETES – EVIDENCE FROM HISTOLOGY, MRI AND
ECHOCARDIOGRAPHY STUDIES
Structural changes
Pathological evidence characterised by myofibrillar hypertrophy with fibrotic strands
extending between muscle fibres to cause diffuse myocardial fibrosis first helped
distinguish cardiomyocyte damage in diabetes[9]. The advancement in non-invasive
imaging techniques has facilitated further delineation and phenotyping of the diabetic
heart.  Alterations  to  left  ventricular  geometry  lead  to  concentric  remodelling,
hypertrophy and eventually increased mass. Left ventricular hypertrophy in diabetes
includes  both  concentric  and eccentric  hypertrophy.  Left  ventricular  concentric
remodelling  has  been  shown  to  have  a  higher  association  with  cardiovascular
mortality  than  eccentric  remodelling  on  both  echocardiographic  and  CMR
studies[62,85-87].
Increased left ventricular mass had initially been shown to be associated with a rise
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Table 1  Myocardial triglyceride content in type 2 diabetes
Study details (Author,Year) Sample population Exclusion Results
Jankovic et al[92], 2012 n = 18 Previous MI, CAD, HF, digitalis use
or thiazolidinediones, previous
insulin use or T1D
Baseline IT myocardial lipid content
0.42% ± 0.12% vs 0.80% ± 0.11% water
signal, (aP = 0.034).
IT (n = 10)
Mean age 56 ± 2 Patients on insulin must have had
insufficient control on oral, HbA1C >
8% and on oral therapy
Myocardial lipid content decreased
by 80% after 10 d IT (P = 0.008). No
significant change in hepatic lipid
content. After 181 ± 49 d, myocardial
lipid content returned to baseline
(0.37 ± 0.06, P = 0.692) Hepatic lipid
content decreased by 31% (bP < 0.001)
DM duration 9 ± 2 yr
6 males
HbA1c 11.1 ± 0.4
Oral therapy (OT) (n = 8)
Mean age 53 ± 2
DM duration 3 ± 1 yr
4 males
HbA1c 9.8% ± 0.7%
Korosoglou et al[119], 2012 n = 58 Unstable condition, clinical signs of
heart failure or angina
contraindications for CMR, insulin
use
Significant association between
myocardial triglyceride content and
mean diastolic strain rate (r = -0.71, cP
< 0.001) and no association was
found between triglyceride content
and perfusion reserve (r = -0.08, P =
NS)
T2D (n = 42)
Mean age 62 ± 6 yr
26 male
Mean BMI 31.6 ± 4.8 kg/m2
HV (n = 16)
Mean age 62 ± 3 yr
10 male
Mean age 62 ± 3 yr
Mean BMI 23.9 ± 2.5
Van der Meer et al[101,155], 2009 n = 72 T2D BP > 150/85 mmHg, previous insulin
or thiazolidinedione use, previous
positive stress echo or arrhythmia,
diabetes related complications or
significant medical problems
No significant change in myocardial
fatty acid uptake at follow up on
either arm. Metformin arm showed a
significant decrease in fatty acid
oxidation and myocardial glucose
uptake. No significant change in
myocardial triglyceride content in
Pioglitazone or Metformin arm after
therapy however there was a
decrease in hepatic triglyceride
content in the Pioglitazone arm
All males
Pioglitazone (n = 39)
Metformin (n = 39)
Baseline age 45-65
HbA1C 6.5%-8.5%
BMI 25-32
Rijzewijk et al[83], 2008 n = 66 Females, HbA1C > 8.5%, BP >
150/80, hepatic impairment or
history of liver disease, substance
abuse, known CVD, DM
complications, contraindication to
MRI, use of lipid lowering therapy.
Myocardial triglyceride content  in
T2D vs controls (0.96% ± 0.07% vs
0.65% ± 0.05%). Hepatic triglyceride
content  in T2D vs controls (8.6% vs
2.2%). Both cases, dP < 0.05 On
univariate analysis, myocardial
triglyceride content correlated with
age, visceral adipose tissue,
cholesterol, plasma glucose and
insulin and hepatic triglyceride
content (eP < 0.05 for all). E/A
independently associated with
myocardial triglyceride content on
multivariate analysis (inverse
correlation)
T2D (n = 38)
All males
mean age 57 ± 1 yr
BMI: 28.1 ± 0.6
Controls (n = 28)
All males
Mean Age: 54 ± 1
BMI: 26.9 ± 0.5
McGavock[82] 2007 n = 134 Age > 70 yr, known CAD, Previous
MI, contraindications to MRI,
thiazolidinedione treatment
↑Subcutaneous, visceral fat and
hepatic triglyceride in O,I and T2D vs
L, ↑myocardial triglyceride content in
I and DM vs L (0.95 ± 0.60 vs 1.06 ±
0.62 vs 0.46 ± 0.30 fat/water content,
fP < 0.05), this remained significant
after adjusted for serum triglyceride,
BMI, age and gender. In multiple
regression model, Subcutaneous and
visceral fat both independent
determinants of myocardial
triglyceride content (gP < 0.05)
however myocardial triclyceride
unrelated to hepatic triglyceride or
diastolic function
Lean(L) (n = 15)
Age 35 ± 3 yr, 47% males
BMI 23 ± 2, non T2D
Overweight/Obese(O): (n = 21) Age
36 ± 12, BMI 32 ± 5, 48% males , non
T2D
Impaired glucose tolerance(I): (n =
20)
Age 49 ± 9, 25% males, BMI 31 ± 6,
T2D (n = 78),
Age 47 ± 10, 47% males BMI 34 ± 7
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DM: Diabetes mellitus; MI: Myocardial infarction; T1D: Type 1 diabetic; CAD: Coronary artery disease; BMI: Body mass index; IT: Insulin therapy.
in HbA1c levels in a HF population[88]. Studies using both echocardiography and MRI
have been successful in showing an increase in left ventricular mass associated with
diabetes independently of other factors[10,62,85,87,89-94]. Table 2 details studies that have
examined  left  ventricular  mass  and  concentric  remodelling  on  MRI  in  T2D.  In
summary, there is a general trend that shows an increase in left ventricular mass.
However, when corrected for body surface area, this does not persist. In two studies,
there remained a higher left ventricular mass/volume ratio, but due to a general
increase in end diastolic volume this difference is obliterated when corrected for
volume.  A  decrease  in  stroke  volume  is  as  expected  in  concentric  remodelling.
Increased left ventricular mass is a known predictor of cardiovascular mortality and
morbidity[95,96].
CMR  T1  mapping  pre  and  post-contrast  allows  calculation  of  myocardial
extracellular volume (ECV) which is a surrogate for diffuse interstitial fibrosis and
correlates with pathology samples obtained in patients with heart failure[97]. Levelt et
al[62]  used  similar  techniques  and concluded that  although there  was  concentric
remodelling  and  evidence  of  diastolic  dysfunction,  there  was  no  evidence  of
expansion of extracellular matrix in people with well-controlled T2D. However, this is
contrary to most existing literature on ECV and T1 mapping to date, which has shown
increased  ECV  and  native  T1  values  in  T2D  compared  to  healthy  controls[98,99].
Swoboda et al[100] also showed increased ECV and native T1 relaxation at baseline in
T2D and demonstrated that treatment with renin-angiotensin-aldosterone system
inhibition led to an improvement in left ventricular ejection fraction and a decrease in
myocardial ECV. The differences in literature on extracellular matrix may be related
to patient selection for the controls. For example, young and healthy controls rather
than age-matched non-diabetics. Sensitivity of different T1 mapping techniques may
also play a small role.
Functional changes
Diabetic  cardiomyopathy  has  mainly  been  linked  with  features  of  diastolic
dysfunction. This is especially apparent in asymptomatic individuals as the earliest
sign of HF. Most of the evidence in imaging of patients with T2D have not shown a
significant decrease in ejection fraction/systolic dysfunction[88,101-103] with the exception
of the Strong Heart Study where a direct correlation of ejection fraction was seen
associated with HbA1c levels[87]. Diastolic dysfunction is now regarded as the first
functional change occurring in diabetic cardiomyopathy.
Strain  is  a  measure  of  tissue  deformation.  As  the  ventricle  contracts,  muscle
shortens longitudinally and circumferentially and thickens radially. The application
of strain to measure deformation is constrained by a number of complexities when the
parameter is measured by echocardiography[104].  Tissue Doppler imaging (TDI) in
echocardiography improved the identification of early diastolic  dysfunction and
recent  developments  in  strain  imaging  on  CMR  has  very  much  improved  the
sensitivity and accuracy of identifying subclinical diastolic dysfunction in the T2D
population. Measurement of strain using CMR is now considered the gold standard.
Strain rate measures the time course of deformation and this can be derived from
speckle tracking echocardiography or measured directly from MRI cine images with
dedicated software programmes of which several are available.
Both longitudinal and circumferential strain have been shown to be impaired in
T2D. Table 3 identifies the larger and more recent studies that have shown early
changes in strain in people with diabetes[11,88,91,94,105-107]. Different studies have studied
and  reported  different  measures  of  strain  making  the  literature  not  directly
comparable. Global longitudinal strain (GLS) has been shown to be decreased in the
diabetic population compared to healthy volunteers in all the studies described across
tissue Doppler, speckle tracking echocardiography and CMR. Additionally, some
studies have shown a decrease in radial strain. One study has shown that peak early
diastolic  strain rate  (PEDSR) and peak systolic  strain rate  are  both decreased in
diabetes even when compared to obese/overweight non-diabetic controls[11]. Strain
and strain rate,  especially PEDSR is a good measure contractility and contractile
reserve. Its application in clinical practice remains in infancy to be used to predict
potential development of heart failure with preserved ejection fraction in the form of a
contractility index. It is widely regarded as a precursor to the onset of heart failure in
T2D and a predictor of cardiovascular mortality and morbidity even in the absence of
symptoms[108,109].
Coronary microvascular dysfunction
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Table 2  Magnetic resonance imaging studies looking at left ventricular mass and concentric remodelling in diabetes
Study details (Author, Year) Sample population Exclusion criteria Main findings
Ng et al[91], 2012 n = 69 Age < 18 yr, arrhythmia, CAD, MI,
RWMA, segmental LGE, EF < 50%,
valve disease
No difference between groups for
LVEDVI, LVESVI, LVMI, LVEF.DMs (n = 50, 35 T1DM) Mean age 51
± 10 yr, 54% males. BMI 26.3 ± 3.7
Controls (n = 19), matched for age (45
± 15), sex (63.2% males) an BMI 26.1 ±
4.4
Wilmot et al[93], 2014 T2D n = 20, mean age 31.8 ± 6.6, BMI
33.9 ± 5.8 kg/m2
Weight > 150 kg, contraindications to
MRI. In diabetic group BMI > 30 (>
27.5 in South Asians)
↑ LVM (85.2 vs 80.8 g, jP = 0.002) and
LVM/Volume (0.54 vs 0.45 g/m2, kP
= 0.029) in participants with diabetes
compared to lean controls. No
significant difference in LVMI
Lean Controls: n = 10, Mean age 30.9
± 5.6, Mean BMI 33.4 ± 2.4, 60% males
Obese Controls: n = 10, Mean age
30.0 ± 6.7, Mean BMI 21.9 ± 1.7, 50%
males
Larghat et al[10], 2014 T2DM: n = 19 Mean age 59 ± 6, 68%
males, BMI 30.81 ± 4.6
Coronary artery Stenosis > 30%
luminal narrowing on angiography,
previous MI, significant heart
disease, contraindications to MRI or
adenosine
↑ LVM (112.8 ± 39.7 vs 91.5 ± 21.3 g, lP
= 0.01) in participants with diabetes.
Participants with diabetes also
showed an increase in LVEDV and
SV, but non indexed
Pre-DM: n = 30 Mean age 57 ± 8, 43%
males, BMI 30.1 ± 5.0
Non DM: n = 46, Mean age 57 ± 7,
41% male, BMI 29 ± 4.9
Levelt et al[62], 2016 T2DM: n = 39, Mean age 55 ± 9, 58%
males, BMI 28.7 ± 5.6
History of CVD, chest pain, smoker,
uncontrolled hypertension,
contraindications to MRI, ischaemia
on ECG, renal dysfunction, insulin
use, significant CAD on CTCA
EF, LVM, LVMI, no significant
difference between groups.
Controls: n = 17, Mean age 50 ± 14 yr ← LVM/Volume (0.98 ± 0.21 vs 0.70 ±
0.12, mP < 0.001), LVDEV (125 ± 30
mL vs 161 ± 39 mL, nP = 0.001) and
lower SV in diabetes
53% males, BMI 27.1 ± 5.0
IT: Insulin therapy; OT: Oral therapy; BMI: Body mass index; CAD: Coronary artery disease; MI: Myocardial infarction; RWMA: Regional wall motion
abnormality; LVEDVI: Left ventricular end diastolic volume index; LVESVI: Left ventricular end systolic volume index; LVMI: Left ventricular mass index;
LVEF: Left ventricular ejection fraction.
Coronary microvascular dysfunction in diabetes is a complex pathophysiological
process, which involves structural, functional and metabolic alterations. It is likely to
be a multifactorial phenomenon, related to changes in perivascular and interstitial
fibrosis[110],  myocardial hypertrophy[111],  reduced capillary density, and autonomic
neuropathy[112].  Coronary  microvascular  dysfunction  has  emerged  among  the
potential mechanisms leading to increased incidence of heart failure[113] and risk of
cardiovascular mortality[3,114]  in patients with diabetes.  Both hyperglycaemia and
dyslipidaemia have been shown to cause abnormal structure and function within the
endothelium. High circulating glucose concentration causes downregulation of nitric
oxide resulting in increased vasoconstriction[115].  This in turn results in increased
vascular  tone,  permeability,  thinning  of  vascular  endothelium,  weakening  of
intercellular junctions, altered protein synthesis and ultimately causes remodelling[115].
Using CMR[10,94,116] and PET[114,117] myocardial perfusion during vasodilator stress has
been shown to be impaired in patients with diabetes[10,94,116]  and in the absence of
epicardial  coronary  artery  stenosis,  this  finding  is  indicative  of  coronary
microvascular dysfunction. Importantly, coronary microvascular dysfunction is an
early precursor of cardiovascular events and was shown to be associated with a 2.5%
annual major adverse event rate that includes cardiovascular mortality,  nonfatal
myocardial  infarction,  nonfatal  stroke,  and congestive  HF even among patients
without epicardial coronary artery stenosis[118]. Consequently, early identification of
coronary microvascular disease may be beneficial in prognosis evaluation and patient
stratification for optimal medical therapy
Using adenosine stress perfusion CMR Larghat et al[10] have assessed myocardial
perfusion reserve in 65 patients with no significant epicardial coronary artery stenosis
on angiography (< 30% coronary luminal stenosis). Left ventricular mass was shown
to be higher in diabetics than non-diabetics (112.8 ± 39.7 g vs 91.5 ± 21.3 g, P = 0.01)
and in diabetics than prediabetics (112.8 ± 39.7 g vs 90.3 ± 18.7 g, P = 0.02). MPR was
lower in diabetics than non-diabetics (2.10 ± 0.76 vs  2.84 ± 1.25, respectively, P =
0.01)[10].  Khan  et  al[11]  have  also  studied  40  young  patients  (mean  age  30  years),
including 20 diabetics and 10 lean and 10 obese controls who underwent CMR. This
study, however, did not show any significant correlation between left ventricular
intracardiac  measures,  including mass,  MPR and perfusion and the  presence  of
T2D[11]. Diastolic dysfunction was found to be associated with TG content but not with
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Table 3  Studies on left ventricular function and myocardial strain in diabetes
Publication and imaging
modality
Group and baseline
characteristics Exclusion Main findings
Ernande et al[107], 2010 T2DM: n = 119, 69 males LVEF < 56%, age < 35 or > 65, signs,
symptoms or history of heart disease,
no RWMA, valve disease, renal
disease, T1DM, poor DM control
(HbA1C > 12%)
↓GLS (-19.3% ± 3% vs -22% ± 2%) and
GRS (50% ± 16% vs 56% ± 12%, nP <
0.003) in participants with diabetes vs
participants without diabetes
Echocardiography Controls: n = 39, 30 males Multivariate analysis showed DM (t
= 3.9, P < 0.001) and gender (t = 3.4, P
= 0.001) independent determinants of
GLS, DM only independent
determinant of GRS.
Ng et al[91], 2012 n = 69 Age < 18 yr, arrhythmia, CAD, MI,
RWMA, segmental LGE, EF < 50%,
valve disease
↓GLS DM vs controls (-16.1% ± 1.4%
vs 20.2% ± 1.0% pP < 0.001)
MRI DMs (n = 50, 35 T1DM) Mean age 51
± 10 yr, 54% males. BMI 26.3 ± 3.7
↓GLS DM T2DM vs T1DM (-15.3% ±
1.2% vs 16.4% ± 1.4%, qP = 0.009)
Controls (n = 19), matched for age (45
± 15), sex (63.2% males) an BMI 26.1 ±
4.4
Khan et al[11], 2014 T2D n = 20, Mean age 31.8 ± 6.6, BMI
33.9 ± 5.8 kg/m2
Weight > 150 kg, contraindications to
MRI. In diabetic group BMI > 30 (>
27.5 in South Asians)
↓PEDSR in DMs vs Lean controls vs
obese controls (1.51 ± 0.24 vs 1.97 ±
0.34 vs 1.78 ± 0.39 s-1) and PSSR (-
21.20 ± 2.75 vs -23.48 ± 2.36 vs -23.3 ±
2.62s-1)
MRI Lean Controls: n = 10, Mean age 30.9
± 5.6, Mean BMI 33.4 ± 2.4, 60%
males.
Obese controls: n = 10, Mean age 30.0
± 6.7, Mean BMI 21.9 ± 1.7, 50% males
Levelt et al[62], 2016 T2D: n = 39, Mean age 55 ± 9, 58%
males.
History of CVD, chest pain, smoker,
uncontrolled hypertension,
contraindications to MRI, ischaemia
on ECG, renal dysfunction, insulin
use, significant CAD on CTCA
↓GLS (-9.6 ± 2.9 vs -11.4 ± 2.8 rP =
0.049) and  mid ventricular (-14.2 ± 2
vs -19.3, sP < 0.001) systolic strain
(PCr/ATP ratio at rest and exercise,
correlated with reduced systolic
strain results; there was also a
negative association between the
myocardial lipid levels and systolic
strain in this cohort)
MRI Controls: n = 17, Mean age 50 ± 14 yr
CTCA: Computed topography coronary angiogram; GLS: Global longitudinal strain; GRS: Global radial strain; PEDSR: Peak early diastolic strain rate;
PSSR: Peak systolic strain rate; RWMA: Regional wall motion abnormality.
impaired myocardial perfusion reserve in another study with patients with T2D with
preserved systolic function[119].
Another study looking at the interplay between metabolic and ischaemic changes
in the hearts  of  people with well-controlled T2D, even in the absence of  arterial
hypertension or significant CAD on computed tomography coronary angiography,
showed  there  were  significant  reductions  in  MPRI  and  evidence  of  blunted
oxygenation response compared with controls. These findings support the concept
that  hypoperfusion  as  a  result  of  microvascular  dysfunction  plays  a  role  in  the
impaired  ability  to  increase  and/or  maintain  myocardial  oxygenation  during
vasodilator stress in diabetes[94].
In a large study of 2783 consecutive patients (1172 diabetics and 1611 non-diabetics)
measuring coronary flow reserve (CFR) by PET[120], they showed that diabetic patients
with preserved CFR have similar  rates of  cardiac events to nondiabetic  patients,
whereas impaired CFR was associated with an adjusted 3.2- and 4.9-fold increase in
the rate of cardiac death for both diabetics and nondiabetics. This raises the question
of whether CFR should be included in a cardiac risk model for patients with diabetes.
However, there is selection bias due to patients recruited consecutively, some had
regional perfusion defects and the results of angiography were not known therefore
the impaired flow reserve cannot be attributed directly to microvascular dysfunction.
In  a  small  (n  =  64)  randomised  trial  comparing  the  effects  of  spironolactone,
hydrochlorothiazide or placebo on coronary flow reserve in T2D assessed by cardiac
positron  emission  tomography,  spironolactone  was  associated  with  modest
improvements in coronary flow reserve (from 2.77 ± 0.82 to 3.10 ± 0.74) compared to
the other two treatment arms (P = 0.01) after six months[117]. The mechanism for this is
thought to be due to expression of the mineralocorticoid receptor in endothelium,
vascular  smooth  muscle  cells,  cardiomyocytes  and  circulating  leukocytes[117].
Mineralocorticoid receptor activation causes vascular inflammation with increased
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ROS  production  and  increased  vascular  damage,  vascular  dysfunction,  and
perivascular  fibrosis.  The  findings  of  this  study  support  the  potential  role  of
mineralocorticoid  use  in  reversing  coronary  microvascular  dysfunction  in  T2D.
However, there was no reporting of cardiovascular outcomes, relatively small sample
size and limited follow up period.
The  evidence  of  the  role  of  coronary  microvascular  dysfunction  in  T2D  is
conflicting. This suggests that the metabolic dysfunction caused by diabetes likely
may predispose to some degree of microvascular dysfunction however these may not
be the main mechanisms contributing to cardiac dysfunction in diabetes.
Therapeutic developments and cardiovascular outcomes
The evidence for pharmacological therapy for heart failure targeted at the diabetic
population thus far has been limited to studies of both patients with and without
diabetes.  ACE-inhibitors  are  recommended within  the  ESC/EASD guidance  for
diabetes and impaired glucose tolerance. The CHARM, ATLAS and HEAAL trials
have  all  shown  the  beneficial  effects  of  ACE  in  HF  in  terms  of  morbidity  and
mortality,  however  subgroup  analyses  showed no  difference  with  and  without
diabetes [121-124].  This  is  similarly  the  case  with  the  use  of  mineralocorticoid
antagonists[125,126], nitrates and hydralazine[127], ivabradine[128] as well as more recently
sacubitril/valsartan[129].
The impact of better glycaemic control on left ventricular systolic and[130] diastolic
function remains debatable due to varying evidence. Previous large studies including
United KingdomPDS[131], ADVANCE[130] , ACCORD[132] and VADT[15] have not shown
an improvement in cardiovascular outcomes with good glycaemic control. A meta-
analysis of 37229 people with T2D data from multiple randomized trials concluded
there  was  no  observed  benefit  of  intensive  glycaemic  control  on  HF  related
outcomes[133]. Patients with T2D who received intensive glucose lowering therapy had
a reduced risk of major adverse cardiovascular events, but there was no effect on total
mortality, cardiac death, stroke, and heart failure[133].
There is also a large body of evidence to suggest T2D therapies may increase the
risk of developing heart failure. This has been particularly the case with dipeptidyl
peptidase-4 (DPP4) inhibitor saxagliptin and thiazolidinediones (TZDs). In SAVOR-
TIMI 53 looking at saxagliptin vs placebo there was a significantly increased risk of
heart failure hospitalisation[134,135]. These patients then went on to have a high rate of
subsequent  death.  The latter  result  was also found in the RECORD trial[136].  The
TECOs trial looking at sitagliptin[17]  and EXAMINE for alogliptin[18],  both against
placebo  there  was  no  increase  in  heart  failure.  Further  studies  are  required  to
consolidate the effects of DPP4 inhibitors on heart failure in T2D. There are current
ongoing studies, CARMELINA (Cardiovascular and Renal Microvascular Outcome
Study With Linagliptin in Patients with Type 2 Diabetes Mellitus; NCT01897532) and
CAROLINA (Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in
Patients With Type 2 Diabetes; NCT01243424), looking at Linagliptin in T2D that may
provide better insight.
More recent studies have shown favourable cardiovascular outcomes with newer
glucose  lowering  agents.  There  have  recently  been  numerous  non-inferiority
cardiovascular outcome trials using newer glucose lowering therapies in T2D, namely
GLP1 – Receptor Agonists and sodium–glucose cotransporter 2 (SGLT2) inhibitors.
Glucagon like peptide 1-receptor agonists
Multiple glucagon-like peptide-1 (GLP-1) receptor agonists in the form of once weekly
exenatide, dulaglutide, albiglutide and semaglutide have been recently developed.
GLP-1  agonists  exert  their  effects  by  stimulating  insulin  secretion,  suppressing
appetite, decreasing circulating glucagon levels and gastric emptying[137]. They have
also  been  associated  with  weight  loss.  The  cardiovascular  benefits  of  GLP-1  is
multifaceted. The first is glycaemic control. Long acting agonists have been shown to
be  better  at  reducing HBA1c than short  term[138].  Despite  the  failure  to  show an
improvement in cardiovascular outcomes with some large studies in the past[15,139,140],
the United Kingdom PDS study that looked at tight glycaemic control at diagnosis
showed a reduction in cardiovascular events after a decade even with similar HbA1c
levels[131]. The second is through blood pressure control. None of the GLP-1 studies
conducted thus far have been specifically to look at its’ effects on blood pressure
however both studies as well as reviews and meta analyses have shown a decrease in
BP of both exenatide and liraglutide compared with placebo and other antidiabetic
drugs[141].  It  has  also  been  shown  to  have  favourable  effects  on  the  vascular
endothelium in that Liraglutide has been shown to improve nitric oxide synthase
(NOS) activity as well as attenuates plasminogen activator inhibitor type 1 (PAI-1)
and vascular adhesion molecule (VAM) within the vascular endothelium. These apply
a protective effect against endothelial dysfunction[142,143]. GLP-1 agonists also appear to
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have  a  cardioprotective  effect  on  atherosclerosis  progression  and  myocardial
ischaemia, and this has been shown with the use of exenatide as an adjunct therapy in
STEMI and thrombolysis[144,145].  GLP-1 agonist use has not been associated with a
significant effect on heart failure hospitalisation.
Large studies examining the impact of GLP-1 agonists on cardiovascular outcomes
in T2D have been summarised in Figure 5. In the LEADER trial, patients with T2D on
Liraglutide had lower rates of cardiovascular death[146].  Similarly SUSTAIN-6 also
looked at GLP-1 agonists with Semaglutide being an injectable version with longer
half-life  have  also  shown  improved  cardiovascular  outcomes.  However,  in  the
EXSCEL[23], Exenatide did not show overall cardiovascular risk benefit compared to
placebo. Most recently, the PIONEER 6 trial has studied the non-inferiority of oral
daily semaglutide against placebo for cardiovascular outcomes[147]. It has been shown
to have a significant reduction in the composite primary outcome of first occurrence
of death from cardiovascular causes, nonfatal myocardial infarction (including silent),
or nonfatal  stroke,  i.e.,  8.6% in the semaglutide group vs  6.6% in placebo, with a
hazard ratio  of  0.79,  95%CI:  0.57-1.11,  P <  0.001  for  non-inferiority,  P  =  0.02  for
superiority. However, when the components of the primary outcome are looked at,
non-fatal  MI  and  death  from  cardiovascular  causes  comes  up  non-significant.
However,  this  study  was  relatively  underpowered  compared  to  the  other
cardiovascular  outcome trials  and this  may explain  why the  reduction  was  not
statistically  significant.  Increasing evidence for  oral  GLP-1 agonists  has  marked
benefits for those who have reservations regarding all previous GLP-1 agonists that
have been in the form of a subcutaneous injection and will allow for better compliance
with the new ADA/EASD guidance to use a GLP-1 agonist as second line therapy in
diabetes. There is a larger phase three cardiovascular outcome trial underway, the
Heart  Disease  Study  of  Semaglutide  in  patients  with  Type  2  Diabetes  (SOUL;
NCT03914326), looking at oral semaglutide against placebo and its effects on lowering
MACE in over 9000 patients. The results of this is eagerly awaited.
Sodium glucose co-transporter 2 inhibitors
In both the EMPA-REG OUTCOME[19] and CANVAS[20] studies (Figure 6) there was a
relative risk reduction in cardiovascular  mortality  and hospitalisation for  HF in
patients  with  T2D.  The  hazard  ratio  for  HF  hospitalisation  in  the  EMPA-REG
OUTCOME trial was 0.65, (0.57, 0.82, P = 0.002) for empagliflozin vs placebo[21]. A
reduction in  hospitalization for  HF was  also  observed with  Sodium glucose  co-
transporter  2  (SGLT2)  inhibitor  Dapagliflozin in  DECLARE-TIMI 58 trial[148].  An
important consideration in interpretation of these results is that the patients in these
studies either had established cardiovascular disease or multiple risk factors for
atherosclerotic cardiovascular disease risk factors and it is uncertain whether the
results can be translated in to lower risk groups with prevention of the development
of HF.
The mechanisms by which SGLT2 inhibitors lower HF hospitalisation rates in T2D
are still  under scrutiny.  However,  it  is  hypothesised to be related to the urinary
sodium and glucose excretion that leads to increased fluid losses resulting in reduced
pre-load and afterload[149]. Secondary effects include fluid loss and blood pressure
lowering. There is also suggestion that SGLT2 inhibitors shift myocardial metabolism
towards ketones, resulting in this having a favourable effect on cardiac energetics[150].
CONCLUSION
Diabetic heart disease is multi-faceted and spans metabolic, structural and functional
changes. Recent advancements in imaging has aided significantly in understanding
the pathophysiology as well as the remodelling and functional changes within the
heart.  Further  research into  the  degree  of  dependence  on fatty  acid  metabolism
instead of glucose in the presence of diabetes is required. The relationship between
the metabolic changes within the heart and functional measures such as myocardial
strain rates as well as triglyceride content will help us better understand how to treat
this disease process. This will also add towards increasing the mechanistic accuracy of
new therapeutic targets.
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Figure 5
Figure 5  Major cardiovascular outcome trials using GLP1 receptor antagonists.
Figure 6
Figure 6  Major cardiovascular outcome trials examining SGLT2 inhibitors.
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